Publications by authors named "Stephen R D Johnston"

73Publications

Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.

Drugs 2019 Nov;79(17):1849-1866

Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40265-019-01208-8
Publisher Site
http://dx.doi.org/10.1007/s40265-019-01208-8DOI Listing
November 2019

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

J Clin Oncol 2018 03 15;36(8):741-748. Epub 2017 Dec 15.

Stephen R.D. Johnston, The Royal Marsden NHS Foundation Trust, London; Lisa S. Williams, Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom; Roberto Hegg, Centro de Referência da Saúde da Mulher; Sergio D. Simon, Hospital Israelita Albert Einstein, São Paulo, Brazil; Seock-Ah Im, Seoul National University College of Medicine, Seoul; In Hae Park, National Cancer Center, Gyeonggi-do, Korea; Olga Burdaeva, Regional Oncology Dispensary, Arkhangelsk; Sergei Tjulandin, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Galina Kurteva, University Cancer Center Hospital, Sofia, Bulgaria; Michael F. Press, University of Southern California, Los Angeles, CA; Hiroji Iwata, Aichi Cancer Center Hospital, Aichi, Japan; Sarah Kenny, Severine Sarp, and Miguel A. Izquierdo, Novartis Pharma AG, Basel, Switzerland; and William J. Gradishar, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.7824
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.7824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444639PMC
March 2018

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

J Clin Oncol 2016 09 6;34(25):2961-8. Epub 2016 Jun 6.

Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.3061DOI Listing
September 2016

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

J Clin Oncol 2016 09 23;34(25):3069-103. Epub 2016 May 23.

Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1487DOI Listing
September 2016

Targeted Combinations for Hormone Receptor-Positive Advanced Breast Cancer: Who Benefits?

J Clin Oncol 2016 Feb 23;34(5):393-5. Epub 2015 Dec 23.

Royal Marsden National Health Service Foundation Trust, London, United Kingdom

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0771DOI Listing
February 2016

Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.

Lancet 2016 Feb 11;387(10021):819-21. Epub 2015 Dec 11.

Department of Medicine, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)01219-2DOI Listing
February 2016

Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.

J Natl Cancer Inst 2015 Oct 6;107(10). Epub 2015 Aug 6.

Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv212DOI Listing
October 2015

Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunction.

Case Rep Oncol 2015 Jan-Apr;8(1):113-21. Epub 2015 Feb 26.

Breast Unit, The Royal Marsden Hospital, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000371720DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376930PMC
April 2015

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Clin Cancer Res 2015 Jul 14;21(13):2932-40. Epub 2014 Nov 14.

The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom. Academic Department of Biochemistry, Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1428DOI Listing
July 2015

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments.

Breast Cancer Res Treat 2014 Jul 15;146(2):245-58. Epub 2014 Jun 15.

Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3016-5DOI Listing
July 2014

Can NOAH guide us to improved survival in breast cancer?

Lancet Oncol 2014 May 20;15(6):550-2. Epub 2014 Mar 20.

The Breast Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70116-0DOI Listing
May 2014

The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?

Curr Oncol Rep 2014 ;16(1):358

Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-013-0358-9DOI Listing
June 2014

Dual HER2 targeting for early breast cancer.

Lancet Oncol 2013 Nov 4;14(12):1145-6. Epub 2013 Oct 4.

The Breast Unit, The Royal Marsden NHS Foundation Trust, Chelsea, London SW3 6JJ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70463-7DOI Listing
November 2013

Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy—overcoming resistance and introducing new agents.

Am Soc Clin Oncol Educ Book 2013

From the Department of Medicine, Royal Marsden NHS Foundation Trust, Chelsea, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e28DOI Listing
November 2015

Taxane benefit in breast cancer--a role for grade and chromosomal stability.

Nat Rev Clin Oncol 2013 Jun 7;10(6):357-64. Epub 2013 May 7.

Cancer Research UK Section of Clinical Trials, The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.67DOI Listing
June 2013

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.

Breast Cancer Res Treat 2013 Feb 3;137(3):755-66. Epub 2013 Jan 3.

Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fulham Road, Chelsea, London, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2399-4
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2399-4DOI Listing
February 2013

Imaging in oncology--over a century of advances.

Nat Rev Clin Oncol 2012 12 13;9(12):728-37. Epub 2012 Nov 13.

Department of Imaging, Royal Marsden Hospital, Fulham Road, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.195DOI Listing
December 2012

The role of chemotherapy and targeted agents in patients with metastatic breast cancer.

Eur J Cancer 2011 Sep;47 Suppl 3:S38-47

Department of Medicine, The Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0959-8049(11)70145-9DOI Listing
September 2011

Metastatic breast cancer in a young adult man after total-body irradiation for acute lymphoblastic leukemia.

J Clin Oncol 2011 Jul 2;29(20):e607-9. Epub 2011 May 2.

Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2011.34.6809
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.34.6809DOI Listing
July 2011

Introduction: are current drug development programmes realising the full potential of new agents?

Breast Cancer Res 2010 Dec 20;12 Suppl 4:S20. Epub 2010 Dec 20.

The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Chelsea, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005740PMC
December 2010

Receptor discordance: does it mean anything?

Clin Breast Cancer 2010 Dec;10(6):419-20

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2010.n.066DOI Listing
December 2010

Are we missing the mTOR target in breast cancer?

Breast Cancer Res Treat 2011 Aug 16;128(3):607-11. Epub 2010 Oct 16.

Royal Marsden Hospital, Chelsea, London, SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-010-1207-2DOI Listing
August 2011

Inflammatory breast cancer--The Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007.

Cancer 2010 Jun;116(11 Suppl):2815-20

Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.25178
Publisher Site
http://dx.doi.org/10.1002/cncr.25178DOI Listing
June 2010

New strategies in estrogen receptor-positive breast cancer.

Clin Cancer Res 2010 Apr 23;16(7):1979-87. Epub 2010 Mar 23.

Department of Medicine, Royal Marsden NHS Foundation Trust, Chelsea, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1823DOI Listing
April 2010

Are current drug development programmes realising the full potential of new agents? The scenario.

Breast Cancer Res 2009 18;11 Suppl 3:S21. Epub 2009 Dec 18.

Department of Medicine, Royal Marsden NHS Foundation Trust, Chelsea, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2440DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797701PMC
May 2010

Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8.

Breast Cancer Res 2009 18;11 Suppl 3:S20. Epub 2009 Dec 18.

Department of Medicine, Royal Marsden NHS Foundation Trust, Chelsea, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797700PMC
May 2010

Ipsilateral breast tumor recurrence: is there any evidence for benefit of further systemic therapy?

Breast J 2009 May-Jun;15(3):268-78

Breast Unit, Royal Marsden NHS Foundation Trust, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1524-4741.2009.00716.xDOI Listing
October 2009

Enhancing the efficacy of hormonal agents with selected targeted agents.

Clin Breast Cancer 2009 Jun;9 Suppl 1:S28-36

Department of Medicine, Royal Marsden Hospital, Chelsea, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2009.s.003DOI Listing
June 2009

Integration of endocrine therapy with targeted agents.

Breast Cancer Res 2008 18;10 Suppl 4:S20. Epub 2008 Dec 18.

Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614846PMC
February 2009

Hormone resistance.

Cancer Treat Res 2009 ;147:1-33

Department of Medicine, Royal Marsden NHS Foundation Trust, Chelsea, London SW4 6JJ, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-0-387-09463-2_9DOI Listing
April 2016

Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?

Cancer 2008 Feb;112(3 Suppl):710-717

Academic Biochemistry Royal Marsden NHS Foundation Trust, Chelsea, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23190DOI Listing
February 2008

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

Breast Cancer Res 2007 ;9(5):112

Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr1763DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242654PMC
March 2008

Small molecule signal transduction inhibitors for the treatment of solid tumors.

Cancer Invest 2007 Aug;25(5):347-65

The Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900701259694DOI Listing
August 2007

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.

J Steroid Biochem Mol Biol 2007 Aug-Sep;106(1-5):180-6. Epub 2007 May 24.

Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsbmb.2007.05.019DOI Listing
November 2007

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

Drugs Today (Barc) 2006 Jul;42(7):441-53

Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://journals.prous.com/journals/servlet/xmlxsl/pk_journal
Publisher Site
http://dx.doi.org/10.1358/dot.2006.42.7.985637DOI Listing
July 2006

A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.

Cancer Chemother Pharmacol 2006 Dec 10;58(6):809-15. Epub 2006 Mar 10.

Department of Medicine, Breast Unit, Royal Marsden NHS Trust, 233 Fulham Road, SW3 6JJ, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-006-0222-9DOI Listing
December 2006

Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.

Clin Cancer Res 2006 Feb;12(3 Pt 2):1061s-1068s

Department of Medicine, Breast Unit, Royal Marsden Hospital NHS Trust, 233 Fulham Road, London SW3 6JJ, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2125DOI Listing
February 2006

Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.

Endocr Relat Cancer 2005 Jul;12 Suppl 1:S75-84

Molecular Endocrinology, Breakthrough Breast Cancer Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Rd, London SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/erc.1.01023DOI Listing
July 2005

Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.

Int J Oncol 2005 Aug;27(2):327-35

Robert H. Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
August 2005

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.

J Steroid Biochem Mol Biol 2005 May;95(1-5):173-81

Department of Medicine-Breast Unit, The Royal Marsden NHS Trust, 233 Fulham Road, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsbmb.2005.04.004DOI Listing
May 2005

Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?

Breast Cancer Res 2005 6;7(3):119-30. Epub 2005 Apr 6.

Department of Medicine - Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr1023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1143577PMC
January 2006

Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations.

Cancer Invest 2004 ;22(5):730-42

Department of Medicine--Breast Unit, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1081/cnv-200032761DOI Listing
December 2004

New targets for therapy in breast cancer: farnesyltransferase inhibitors.

Breast Cancer Res 2004 6;6(6):262-8. Epub 2004 Oct 6.

Department of Medicine, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr947DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064090PMC
April 2005

Novel systemic therapies for breast cancer.

Surg Oncol 2003 Dec;12(4):277-87

Department of Medicine-Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suronc.2003.11.001DOI Listing
December 2003

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Best Pract Res Clin Endocrinol Metab 2004 Mar;18(1):47-66

CRC Department of Medical Oncology, University of Manchester, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beem.2003.08.002DOI Listing
March 2004

Aromatase inhibitors for breast cancer: lessons from the laboratory.

Nat Rev Cancer 2003 Nov;3(11):821-31

Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nrc1211
Publisher Site
http://dx.doi.org/10.1038/nrc1211DOI Listing
November 2003

Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.

Cancer Res 2003 Oct;63(19):6516-22

Academic Department of Biochemistry, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, U.K.

View Article

Download full-text PDF

Source
October 2003

BMS-214662 (Bristol-Myers Squibb).

IDrugs 2003 Jan;6(1):72-8

Department of Medicine (Breast Unit), Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK.

View Article

Download full-text PDF

Source
January 2003

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

J Biol Chem 2003 Aug 29;278(33):30458-68. Epub 2003 May 29.

Academic Department of Biochemistry, Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M305226200DOI Listing
August 2003

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Clin Cancer Res 2003 Jan;9(1 Pt 2):524S-32S

Departments of Medicine and Academic Biochemistry, Royal Marsden Hospital and Institute of Cancer Research, London SW3 6JJ, United Kingdom.

View Article

Download full-text PDF

Source
January 2003

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.

J Steroid Biochem Mol Biol 2002 Aug;81(4-5):333-41

Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-0760(02)00074-2DOI Listing
August 2002

Fulvestrant (AstraZeneca).

Curr Opin Investig Drugs 2002 Feb;3(2):305-12

Department of Medicine, Royal Marsden Hospital and Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
February 2002